<DOC>
	<DOCNO>NCT01384877</DOCNO>
	<brief_summary>This study 's primary objective test hypothesis single infusion subcutaneous lidocaine cause clinically useful reduction cancer pain within 48 hour infusion last minimum 7 day . Subjects receive either lidocaine placebo , follow least 3 week later alternate agent .</brief_summary>
	<brief_title>Subcutaneous Lidocaine For Cancer-Related Pain</brief_title>
	<detailed_description>Ten mg/kg lidocaine infuse subcutaneously via Baxter infusor 5.5 hour period ambulatory adult cancer patient aworst pain score least 4 10 despite therapy least one opioid plus appropriate oral adjuvant analgesic ( ) . A clinically useful reduction pain define either 2-point reduction ( 0-10 scale ) bad pain experience 24-hour period , ≥30 % reduction 24-hour opioid requirement . The secondary objective 1 ) determine whether significant toxicity occur result infusion . For study significant toxicity consider adverse event either lead infusion terminate , lead medical intervention , prescribe another medication equivalent treatment , 2 ) determine effect Lidocaine infusion QOL parameter measure Patient Outcome Scale ( POS ) Questionnaire 3 ) determine duration response lidocaine infusion .</detailed_description>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Male female patient 18 year age older In outpatient refer BCCA PSMPC Clinics diagnosis cancer Subjects must somatic , visceral neuropathic pain related cancer Pain intensity , measure bad pain score last 72 hour ≥4 010 numerical rating scale Must try least one opioid medication without adequate response significant sideeffects least one week For neuropathic pain , must also try least one adjuvant analgesic , tricyclic ( unless contraindicate ) anticonvulsant without adequate response significant sideeffects least one week Life expectancy &gt; 3 month Must able communicate symptom indicate potential toxicity Lidocaine Must competent caregiver home Must willing remain within 30 minute Cancer Centre infusion Clinically significant cardiac disease , i.e , cardiac failure , atrial fibrillation slow ventricular rate ( &lt; 60 ) , degree heart block New analgesic treatment initiated time frame might effect within one week study drug . Hyper hypokalemia . Liver failure ( bilirubin ≥ 25 mmol/L ) . Renal failure ( Creatinine clearance &lt; 50 % normal ) Uncontrolled hypertension ( &gt; 160/90 ) . Hypotension ( systolic &lt; 90 ) . Uncontrolled seizure . Planned initiation chemotherapy , radiotherapy bisphosphonates within 30 day prior treatment study drug . Received investigational drug within 30 day prior study . History allergy lidocaine topical , local infusional anesthetic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
	<keyword>Lidocaine</keyword>
	<keyword>Sodium Channel Blockers</keyword>
</DOC>